The EXAMINE CVOT assessed the cardiovascular safety of alogliptin in patients with type 2 diabetes and acute coronary syndrome. This module details the study outcomes.

Rate this content
  • EXAMINE: trial design
  • EXAMINE: baseline characteristics
  • EXAMINE: CV disease at baseline
  • EXAMINE: renal function at baseline
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go